Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Movement | Bambusa Therapeutics (BBTX.US) debuts on the US stock market, shares drop over 8%

US Stock Movement | Bambusa Therapeutics (BBTX.US) debuts on the US stock market, shares drop over 8%

智通财经智通财经2026/10/30 16:23
Show original

As of press time, the stock is down over 8%, trading at $14.685.

According to Zhihui Finance APP, on Friday, Bambusa Therapeutics (BBTX.US) debuted on the US stock market. As of press time, the stock had fallen more than 8%, trading at $14.685. The IPO price was $16. Bambusa Therapeutics is a Boston-based clinical-stage biopharmaceutical company focused on developing next-generation long-acting bispecific antibody drugs for the treatment of immune system and inflammatory diseases. These drugs are capable of simultaneously targeting two disease-related biological targets, aiming to improve treatment efficacy, extend the duration of action, and reduce the frequency of patient dosing. The company’s leading drug candidate, BBT001, is being developed for the treatment of atopic dermatitis (eczema), chronic spontaneous urticaria, and other skin diseases; another candidate, BBT002, mainly targets asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. In addition, the company is also developing early-stage drugs for inflammatory bowel diseases and autoimmune diseases.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Bloomberg Economists: Anthropic's IPO May Signal the End of the AI Boom

Bloomberg economist Anna Wong believes that Anthropic's actual price per million tokens has dropped significantly since September. Although token usage has surged, its market share has actually declined, indicating that its technological edge has not translated into lasting pricing power. An IPO would bring the pricing and profit margins of cutting-edge AI into the public market for quarterly scrutiny; if its pricing power is weaker than what is implied by its valuation, the AI sector might see an accelerated correction in valuations.

华尔街见闻•2026/11/19 20:06